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Summary: Purpose: To investigate the relation between vas- 
cular determinants and epilepsy in an elderly population. 
Methods: This is a cross-sectional, community-based, case- 
control study. The total study population was comprised of 
4,944 subjects, 65 of whom had epilepsy which conformed to 
International League Against Epilepsy (ILAE) criteria. Vascu- 
lar determinants that were evaluated included a history of 
stroke or myocardial infarction, peripheral vascular disease, 
hypertension, serum total cholesterol and left ventricular hy- 
pertrophy. Multivariate logistic regression analysis was used to 
calculate prevalence odds ratios (OR), adjusted for age and 
gender, as a measure of the strength of the associations. 
Results: A history of stroke was strongly associated with 
lifetime epilepsy (OR 3.3; 95% CI [Confidence Interval] 1.3- 
8.5), as well as with late-onset epilepsy (OR 3.1; 95% CI 0.9- 
10.6). All vascular determinants were associated with lifetime 
epilepsy and late-onset epilepsy, with odds ratios >1. When 
stroke patients were excluded, the odds ratios were statistically 
significant for the relationships between total cholesterol and 
late-onset epilepsy (OR 1.3, 95% CI 1 .O-1.6) and left ventricu- 
lar hypertrophy and late-onset epilepsy (OR 2.9, 95% CI 1.0- 
8.6). Furthermore, presence of any of these vascular indicators 
was twice as common among subjects with late-onset epilepsy 
as compared with subjects without epilepsy (OR 2.0, 95% CI 
0.9-4.2), and this was statistically significant when stroke pa- 
tients were excluded (OR 2.1, 95% CI 1.04.7). 
Conclusions: These results suggest that there may be a rela- 
tionship between vascular factors and the risk of late-onset 
epilepsy, apart from the relationship that exists through clini- 
cally overt stroke. Key Words: Epilepsy-Epidemiology- 
Case control study-Risk factors-Vascular factors. 
Epilepsy is one of the most common neurological dis- 
orders in the elderly (1-3). From the 1960s to the 1980s, 
the incidence of epilepsy decreased among children and 
increased among elderly subjects (4,5). Most cases of 
epilepsy are idiopathic or cryptogenic, and in only 40- 
50%, the epilepsy is attributed to an identified cause 
(5,6). In the elderly, stroke is the most commonly iden- 
tified cause of epilepsy (3,7-9). It has been suggested 
that other vascular determinants or silent infarcts may 
underlie some of the idiopathic or cryptogenic cases in 
the elderly (10-12,23). We conducted a population- 
based cross-sectional, case-control study to explore the 
relationship between vascular determinants and epilepsy 
in the elderly. 
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SUBJECTS AND METHODS 
Study design 
The study was conducted as part of the Rotterdam 
Study, a community based prospective followup study of 
all persons of a 5 5  years, living in the district of Om- 
moord in Rotterdam (13). The baseline survey took place 
from June 1990 to June 1993. From June 1991 on, all 
subjects were screened for epilepsy (2). Throughout the 
Rotterdam Study, subjects were surveyed in random 
clusters. The total cohort consisted of 7,983 participants 
(response 78%), and 5,559 of these were seen in the 
period in which we screened for epilepsy. The standard 
Rotterdam Study protocol was comprised of a home in- 
terview, followed by physical examinations conducted in 
a research center. The screening and diagnostic proce- 
dures for epilepsy have been described in detail else- 
where (2). In short, the screening for epilepsy was con- 
ducted during the home interview by a trained research 
assistant and consisted of 1 question, directly asking 
whether the subject had epilepsy or had epileptic sei- 
zures, and 3 questions about possible symptoms of epi- 
1216 
VASCULAR DETERMINANTS OF EPILEPSY 1217 
lepsy, that were taken from the World Health Organiza- 
tion (WHO) research protocol for screening of neuro- 
logical disorders in developing countries (14). In 
addition, all current drug prescriptions were registered 
and classified according to the Anatomical Therapeutic 
Chemical (ATC) classification index (15). Screen- 
positives were persons who themselves reported epilepsy 
or seizures, or used antiepileptic drugs (ATC code N03), 
or answered “yes” to at least 2 of the 3 WHO questions. 
For all screen-positives, additional information was 
obtained from medical records of general practitioners 
and specialists including EEG and CT scan reports, or- 
if no further information were available from medical 
records-through a telephone interview conducted by a 
specially trained physician who took a detailed medical 
and seizure history. If indicated, the subject was reinter- 
viewed by 1 of 4 epileptologists. All 313 screen-positives 
were subsequently reviewed by a panel consisting of the 
study physician and the 4 epileptologists, which decided 
whether a subject had epilepsy and, if so, classified the 
epilepsy according to the classification of the ILAE (16). 
For the current study, we included as cases subjects who 
were identified with a diagnosis of epilepsy according to 
ILAE criteria (16). The reference population consisted of 
all screen-negative subjects (n = 5246) and of the 
screen-positive subjects in whom a diagnosis of epilepsy 
could be excluded (n = 220). Patients with single acute 
symptomatic seizures were excluded from the study (n 
= 7). We also excluded all subjects (patients and con- 
trols) with dementia, because information about the vari- 
ous risk factors could not be obtained reliably, in most 
instances. Furthermore, we may have misclassified some 
demented epilepsy cases as nonepileptic, due to under- 
reporting of seizures and symptoms. This left 65 cases 
and 4,944 reference subjects. 
Of the cases, 27 had localization-related epilepsy, 5 
had generalized epilepsy, 20 had undetermined epilepsy, 
and 13 were classified as special syndromes because they 
had suffered from a cryptogenic seizure, after which an- 
tiepileptic drug (AED) treatment was started. 
Measurements 
The baseline examinations of the Rotterdam Study in- 
cluded an interview at each participant’s home, during 
which information on current health status, medical his- 
tory, drug prescriptions and actual use, smoking behav- 
ior, and other information, was obtained by means of a 
computerized questionnaire; this was followed in each 
case by several clinical examinations at a research center. 
A history of stroke, myocardial infarction, head 
trauma with loss of consciousness, and bacterial menin- 
gitis were assessed by direct questioning. For a diagnosis 
of stroke, symptoms should have been present for at least 
24 h; and confirmation of the diagnosis by a treating 
physician was required. Myocardial infarction was de- 
fined as self-reported myocardial infarction with hospital 
admission for myocardial infarction or electrocardio- 
gram (ECG) confirmation. Ankle systolic blood pressure 
was determined with the subject in supine position at 
both right and left posterior tibia1 arteries with a Doppler 
ultrasound transducer, by using a random zero sphygmo- 
manometer (cuff size 38 x 14 cm). Peripheral arterial 
disease was considered present when the left or right 
ankle to brachial systolic blood pressure ratio (ankle- 
brachial index) was <0.90 (17). Serum total cholesterol 
was determined with an automated enzymatic procedure 
(18). The presence of left ventricular hypertrophy was 
assessed in resting 12-lead ECGs, which were made at 
the research center with an ACTA Gnosis IV machine 
(Esaote/Biomedica, Florence, Italy) and digitally stored. 
ECGs were analyzed by the Modular ECG Analysis Sys- 
tem (MEANS) computer program, which has been evalu- 
ated extensively by the developers themselves and by 
others (19,20). 
Analysis 
We used logistic regression analysis to calculate odds 
ratios as a measure of the strength of the association 
between each presumed risk factor and epilepsy, adjusted 
for age and gender. We evaluated the risk of head trauma 
with loss of consciousness and bacterial meningitis, to 
compare with the vascular determinants and especially 
with stroke, and as a validity check on our data. The age 
at onset of epilepsy was compared with the age at first 
occurrence of stroke, myocardial infarction, head trauma, 
and meningitis, to ensure that the onset of epilepsy oc- 
curred after the development of these risk factors in our 
study. For epilepsy patients, reported dates were checked 
with medical records. Subjects who developed these con- 
ditions after onset of epilepsy were classified as negative 
for the specific risk factor. We assessed whether vascular 
determinants were associated with epilepsy, indepen- 
dently from the relation between stroke and epilepsy, 
through a multivariate model in which we adjusted for 
stroke, as well as through an analysis from which stroke 
patients were excluded. We performed separate analyses 
for lifetime epilepsy (epilepsy at some time during life, 
no matter what the age at onset) and late-onset epilepsy 
(i.e., onset age >40 years). 
Some studies reported that AEDs may increase the 
cholesterol level (21,22). Therefore, we did a subanalysis 
to study the relationship between total cholesterol and 
epilepsy, for which we excluded all persons who were 
using AEDs at the time of the examination (n = 42). 
Left ventricular hypertrophy results mainly from long- 
standing hypertension. Hesdorffer et al. reported an as- 
sociation between left ventricular hypertrophy and the 
risk of unprovoked seizures in subjects not treated with 
diuretics, but not in subjects treated with diuretics (23). 
To evaluate this in our data, we performed an analysis in 
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which we adjusted additionally for antihypertensive 
treatment. Also, we did a subanalysis stratified according 
to antihypertensive treatment. 
RESULTS 
Table 1 shows the distribution of the study population 
according to age, gender, and the determinants of inter- 
est. The control group was slightly older than the case 
group (p = 0.015). The proportion of women did not 
differ significantly between groups (p = 0.45). 
Table 2 shows the ORs and 95% CIS for the associa- 
tion of each presumed risk factor with lifetime epilepsy 
(n = 65) and with late-onset epilepsy (n = 39). A his- 
tory of stroke showed a statistically significant associa- 
tion with lifetime epilepsy, with an adjusted OR of 3.3 
(95% CI: 1.3-8.5); this changed little when confined to 
late-onset epilepsy. The adjusted OR per mmol/L in- 
crease of serum total cholesterol was 1.1 (95% CI: 0.9- 
1.3) for lifetime epilepsy, and 1.3 (95% CI: 1.0-1.6) for 
late-onset epilepsy. After excluding the AED users, this 
OR became 1.0 (95% CI: 0.8-1.3) for lifetime epilepsy, 
but remained 1.3 (95% CI: 1.0-1.8) for late-onset epi- 
lepsy. When adjusted only for age and gender, the ORs 
of left ventricular hypertrophy were 1.5 (95% CI: 0.5- 
4.4) for lifetime epilepsy and 2.6 (95% CI: 0.9-7.6) for 
late-onset epilepsy. These remained almost the same 
when we added antihypertensive drug use to the regres- 
sion models, or when we stratified for antihypertensive 
drug use. Myocardial infarction and peripheral arterial 
disease showed positive associations with both lifetime 
epilepsy and late onset epilepsy, but these were not sta- 
tistically significant. Presence of any vascular determi- 
nant, other than stroke, was twice as common among 
subjects with epilepsy as compared to those without. His- 
tory of head trauma with loss of consciousness and bac- 
terial meningitis were significantly associated with life- 
time epilepsy, but the ORs were slightly smaller and not 
statistically significant when the association was con- 
fined to late-onset epilepsy. When the relationship be- 
TABLE 1. Description of the study population [values are 
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History of myocardial infarction (%) 
Total cholesterol (mmoV1) 
Left ventricular hypertrophy (%) 
History of head trauma (%) 
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SD, Standard deviation. 
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TABLE 2. Odds ratios (OR) and 95% confidence intervals 
(95% CI) for  the association between each putative risk 
factor and epilepsy, adjusted for age and gender 
Lifetime epilepsy Late-onset 
(n = 39) (n = 65) 
Epilepsy 
covariates OR 95% CI OR 95% CI 
Vascular determinants 
Stroke 
Total cholesterol (mmol/l) 
Left ventricular hypertrophy 
Myocardial infarction 
Peripheral arterial disease 




































" Defined as total cholesterol >6.5 mmol/l or previous myocardial 
infarction or peripheral arterial disease or left ventricular hypertrophy. 
OR, odds ratio; CI, confidence interval. 
tween each vascular determinant and lifetime and late- 
onset epilepsy was assessed while adjusting for age, gen- 
der, and all other vascular factors, the strength of the 
associations remained largely the same. 
To assess the relationship between vascular determi- 
nants and epilepsy independently from the relationship 
between stroke and epilepsy, we then excluded stroke 
patients from our analysis (Table 3). For most of the 
variables, this hardly changed the results. However, for 
left ventricular hypertrophy, the association became 
stronger, and for late-onset epilepsy statistically signifi- 
cant (OR 2.9; 95% CI 1.0-8.6). The presence of any 
vascular determinant was significantly associated with 
both lifetime epilepsy (OR 1.8; 95% CI: 1.0-3.2) and 
late-onset epilepsy (OR 2.1; 95% CI: 1.04.7). 
DISCUSSION 
In this study, we assessed vascular correlates of epi- 
lepsy in an elderly population. We found, as expected, 
that a previous stroke was strongly associated with the 
risk of epilepsy, but that other vascular risk factors were 
also more frequent in subjects with epilepsy, and the 
TABLE 3. Odds ratios (OR) and 95% confidence intervals 
(95% CI) for  the association between each vascular risk 
factor and epilepsy, adjusted for age and gender. Subjects 
with a previous stroke are excluded 
Lifetime epilepsy Late-onset 
Epilepsy covariates OR 95% CI OR 95%CI 
Total cholesterol (mmol/l) 1.1 0.9-1.3 1.3 1.0-1.6 
Left ventricular hypertrophy 1.7 0.6-4.8 2.9 1.0-8.6 
Myocardial infarction 1.5 0.6-3.9 1.8 0.6-5.4 
Peripheral arterial disease 1.6 0.8-3.2 1.5 0.63.6 
Any vascular determinant" 1.8 1.0-3.2 2.1 1.0-4.7 
a Defined as total cholesterol >6.5 mmolll or previous myocardial 
infarction or peripheral arterial disease or left ventricular hypertrophy. 
CI, confidence interval; OR, odds ratio. 
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difference was statistically significant, even in the ab- 
sence of stroke. 
The effect was stronger when the analyses were con- 
fined to late-onset cases, suggesting that vascular risk 
factors are of particular relevance for epilepsy that de- 
velops later in life. Cross-sectional case-control studies 
are often hampered by the potential for bias. The strength 
of our study is that it was population-based, and that both 
cases and controls underwent a careful screening for sei- 
zures and epilepsy, thereby reducing the possibility of 
selection-bias. Also, the likelihood of serious informa- 
tion bias was minimized because all vascular and other 
determinants were assessed as part of the baseline pro- 
tocol of the Rotterdam Study, without the interviewer 
knowing whether the subject had epilepsy. Potentially 
more serious concerns are that the study is based on 
prevalent cases and that risk factors were assessed after 
onset of epilepsy. Because prevalence is the result of 
incidence of, as well as survival with, the disease, in an 
analysis based on prevalent cases, factors influencing 
survival may lead to spurious associations. We consider 
it unlikely, however, that vascular risk factors have af- 
fected survival differently in subjects with, as compared 
to subjects without, epilepsy. As for the assessment of 
risk factors, for stroke, myocardial infarction, head 
trauma, and meningitis, we took care to include only 
events that had occurred before onset of epilepsy. For 
some of the other vascular factors, like left ventricular 
hypertrophy and peripheral arterial disease, we cannot 
exclude that these developed partly after onset of the 
epilepsy. However, because it is very unlikely that these 
developed as a result of the epilepsy, they can be inter- 
preted as reflecting the proneness to vascular disease. 
Another possible problem is that population-based 
studies of the lifetime prevalence of epilepsy may suffer 
from recall bias and under-reporting, in particular in un- 
der-reporting of early-onset epilepsy in remission (2), 
and one might wonder whether this has invalidated our 
study. For other, well-known, risk factors for epilepsy we 
found ORs with a magnitude very similar to those re- 
ported by other authors. Head trauma with loss of con- 
sciousness was, in our study, associated with lifetime 
epilepsy with an OR of 2.7 (95% CI 1.64.7) and bac- 
terial meningitis with an OR of 4.6 (95% CI 1.1-9.7). 
This fits well with results reported by Hauser, who found 
ORs of 2.2 and 5.0, respectively (lo), and lends further 
credence to our data. 
Stroke is commonly accepted as an important cause of 
seizures in the elderly (9,24-28). We found some indi- 
cation for a relationship with vascular determinants apart 
from the relationship with stroke. There are two possible 
explanations. First, it may be that several subjects with 
epilepsy and vascular determinants but without self- 
reported stroke, actually did have a stroke that was never 
recognized (silent infarct) or not reported. An alternative 
explanation would be that diffuse cerebral damage asso- 
ciated with vascular disease can make the brain more 
vulnerable and increase the risk of epilepsy, even without 
clear infarction of brain tissue. Since we did not perform 
brain-imaging on all our patients, we are unable to dis- 
tinguish between the 2 possibilities. 
In conclusion, this study suggests that vascular risk 
factors are associated with an increased risk of epilepsy, 
either through silent infarcts or through noninfarct 
mechanisms. This corroborates the hypothesis that vas- 
cular disease may be underlying a sizeable proportion of 
cryptogenic cases of epilepsy in the elderly. These find- 
ings need to be confirmed in a prospective study based 
on incident cases. 
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